+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
In Vivo CRO Market by Type, Service Type, Modality, Indication, End User - Global Forecast to 2030- Product Image
In Vivo CRO Market by Type, Service Type, Modality, Indication, End User - Global Forecast to 2030- Product Image
Sale

In Vivo CRO Market by Type, Service Type, Modality, Indication, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666068
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The In Vivo CRO Market grew from USD 6.01 billion in 2024 to USD 6.58 billion in 2025. It is expected to continue growing at a CAGR of 9.75%, reaching USD 10.50 billion by 2030.

Unveiling the Dynamics of the In Vivo CRO Landscape

The In Vivo Contract Research Organization arena stands at a critical juncture as innovation converges with evolving regulatory and economic pressures. This executive summary offers a panoramic view of the forces shaping preclinical and early-stage drug development services, where in vivo studies continue to prove indispensable for safety, efficacy, and translational research. By articulating the most significant trends, tariff impacts, and strategic segmentations, this document equips stakeholders with an actionable understanding of an industry in transformation.

Through a balanced examination of scientific advancements, operational shifts, and emerging marketplace dynamics, this overview situates decision-makers to anticipate challenges and seize opportunities. It underscores how the interplay between technological integration, global policy changes, and customer demand patterns is steering the In Vivo CRO landscape toward greater efficiency and value creation. Ultimately, this introduction frames the narrative for the subsequent deep dive into transformative shifts, tariff repercussions, segmentation insights, regional performance, and strategic recommendations.

Revolutionary Forces Reshaping In Vivo Contract Research

The In Vivo CRO environment is experiencing a rapid evolution driven by advances in digital platforms, artificial intelligence, and enhanced data analytics. These technological breakthroughs are streamlining study design, enabling real-time monitoring of animal models and generating high-accuracy datasets that accelerate decision-making. Simultaneously, integrated service models are gaining traction as sponsors seek single-point accountability for comprehensive preclinical workflows, from protocol design to regulatory submission.

Concurrently, the industry is witnessing a shift toward precision-driven research through genetically engineered models and humanized systems that offer higher translational relevance. Outsourcing strategies are pivoting away from purely cost-driven considerations toward partnerships defined by scientific expertise, specialized capabilities, and quality assurance. Moreover, regulatory authorities are harmonizing guidelines and emphasizing reproducibility, which is fostering tighter collaboration between CROs and regulators to streamline study approvals and ensure compliance.

Navigating the 2025 United States Tariff Wave

The implementation of broadened tariff measures in 2025 has imposed a notable burden on the In Vivo CRO ecosystem, particularly affecting imports of specialized equipment, reagents, and animal models. This escalation in import duties has sharpened cost pressures across laboratory operations, compelling organizations to re-evaluate their procurement strategies and supply chain resilience. In response, many providers are negotiating long-term supplier agreements, leveraging domestic sourcing, and exploring alternative suppliers in allied markets to mitigate expense volatility.

Furthermore, the ripple effects of these charges are driving CROs to enhance operational efficiencies and optimize capacity utilization. Some firms have accelerated investments in automation and modular laboratory platforms to offset margin compression, while others are consolidating high-volume testing in fewer sites to achieve economies of scale. As a result, strategic agility has become a critical differentiator, compelling industry participants to balance cost containment with the maintenance of rigorous quality and regulatory standards.

Dissecting the In Vivo CRO Market Through Strategic Segmentation

A layered segmentation framework reveals how diverse dimensions of in vivo contract research converge to define distinct opportunity spaces. When exploring Type-based analyses, both Rodent and Non-Rodent models serve as foundational pillars, each offering unique translational advantages and operational demands. Parallel to this, Service Type classification spans areas such as Clinical Services, Consulting & Strategy, Laboratory Services, Preclinical Services, Regulatory Services, and Toxicological & Safety Assessment, highlighting how integrated and niche service offerings coexist to meet varying sponsor needs.

Modality segmentation further delineates projects focused on Small Molecules versus those centered on Large Molecules, underscoring differences in pharmacokinetic profiling, formulation challenges, and regulatory pathways. Indication-based insights showcase robust activity in Therapeutic Areas like Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, and Respiratory Disorders. Within Oncology, solid tumors and hematological malignancies demand specialized tumor models and efficacy assays, whereas cardiovascular research concentrates on coronary artery disease and heart failure models with precise hemodynamic measurements. In Infectious Diseases, bacterial and viral infection models drive safety and efficacy evaluations, while neurodegenerative and psychiatric studies offer insights into complex central nervous system disorders. Respiratory assessment ranges from asthma to chronic obstructive pulmonary disease models, each requiring controlled exposure systems and pulmonary function monitoring.

Finally, End User segmentation spotlights Academic & Research Institutions, Government & Regulatory Organizations, Medical Device Companies, and Pharmaceuticals & Biotechnology Companies as key demand centers. Each end user engages with the In Vivo CRO sector through distinct program priorities-from hypothesis-driven academic exploration and public health initiatives to device biocompatibility testing and late-stage drug candidate validation. This multifaceted segmentation approach clarifies the competitive landscape, enabling providers to tailor their value propositions with precision.

Regional Pillars Driving In Vivo CRO Growth Worldwide

Regional analysis highlights how economic, regulatory, and scientific ecosystems shape in vivo contract research trajectories across geographies. In the Americas, a robust network of biopharmaceutical hubs supported by advanced infrastructure and progressive regulatory frameworks fuels high-volume preclinical and translational programs. The United States remains the focal point for large-molecule innovation and first-in-class drug testing, while emerging life science clusters in Canada and Latin America present cost-optimized study options and collaborative research initiatives.

Meanwhile, the Europe, Middle East & Africa region combines mature innovation centers in Western Europe with rapidly growing research investments in parts of Eastern Europe, the Gulf states, and South Africa. Harmonized regulatory standards across the EU simplify cross-border study execution, and expanding clinical research networks in the Middle East enhance access to diverse patient populations. However, varying import regulations and logistical hurdles call for adaptive site management strategies to ensure seamless protocol delivery.

Asia-Pacific continues to gain prominence as a cost-competitive powerhouse, driven by substantial government funding, growing scientific talent pools, and a surge in biotechnology ventures. China, Japan, South Korea, and Australia are leading investments in novel animal models and high-throughput screening capabilities. As capacity expands, sponsors are increasingly leveraging the region’s efficiency advantages to balance development timelines and budget requirements without compromising on data integrity.

Competitive Landscape and Leading Innovators in In Vivo CRO

Key companies within the in vivo CRO domain are forging competitive advantages through strategic acquisitions, platform expansions, and specialized service offerings. Leading sponsors have prioritized vertical integration by incorporating advanced imaging, biomarker discovery, and preclinical safety assessment services under single operational umbrellas to deliver end-to-end solutions. Others have carved out differentiated positions by focusing on high-value modalities such as immuno-oncology, gene therapy, and neuropharmacology, securing partnerships with academic institutions to co-develop proprietary animal models.

Moreover, industry frontrunners are investing heavily in quality management systems and digital infrastructures to uphold compliance while enhancing data transparency. Collaborative programs with regulatory agencies have streamlined approval timelines and fortified reputational capital. At the same time, mid-tier and specialized providers are capitalizing on agility, offering bespoke project customization and localized expertise in emerging therapeutic areas. This competitive mosaic underscores a dynamic market where innovation, scale, and regulatory alignment determine leadership.

Strategic Imperatives for Industry Leadership in In Vivo Services

Industry leaders should capitalize on digital transformation by integrating automation and artificial intelligence into study execution and data management workflows. By doing so, they will not only accelerate project timelines but also reinforce data quality and regulatory compliance. Establishing strategic alliances with suppliers of critical equipment and consumables will mitigate the financial impacts of tariffs, ensuring predictable cost structures and uninterrupted operations.

Diversification across therapeutic modalities and geographic footprints can buffer against region-specific regulatory fluctuations and economic uncertainties. Investing in niche expertise, such as advanced imaging or humanized animal models, will differentiate service portfolios and command premium pricing. Moreover, fostering transparent collaboration with regulatory bodies will facilitate streamlined approvals and enhance credibility. Finally, embedding sustainability practices into facility management and supply chains will resonate with stakeholder expectations and support long-term viability.

Rigorous Research Methodology Underpinning Our Analysis

This analysis draws upon a rigorous, multi-tiered research design combining secondary data harvesting, expert interviews, and qualitative triangulation. Secondary research involved a comprehensive review of scientific publications, regulatory guidelines, and industry reports to establish foundational insights. In parallel, structured discussions with C-level executives, laboratory directors, and regulatory specialists provided firsthand perspectives on prevailing challenges and emerging trends.

Data integrity was ensured through cross-validation of sources and iterative feedback loops with subject matter experts. Quantitative analyses leveraged curated databases to map service footprints, model utilization rates, and regional capacities. Analytical frameworks were then applied to interpret segmentation patterns and competitive dynamics. Throughout, adherence to high standards of transparency and methodological rigor supported the generation of actionable intelligence tailored to decision-makers in the in vivo CRO ecosystem.

Synthesis and Path Forward for In Vivo Contract Research

In synthesizing the evolving dynamics of the in vivo contract research sector, this summary highlights the confluence of technological innovation, economic policy shifts, and strategic differentiation. By understanding the nuanced impacts of tariffs, segmentation frameworks, and regional capabilities, stakeholders can navigate complexity with confidence. The competitive landscape underscores the necessity of agility, quality, and collaborative engagement to maintain leadership.

Moving forward, those who balance investment in advanced platforms with disciplined cost management and regulatory foresight will unlock the greatest value. As the sector continues to mature, disciplined segmentation and tailored solutions will differentiate the trailblazers from the also-rans. This conclusion distills the critical takeaways and sets the stage for informed decision-making in an industry defined by rapid change.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Non-Rodent
    • Rodent
  • Service Type
    • Clinical Services
    • Consulting & Strategy
    • Laboratory Services
    • Preclinical Services
    • Regulatory Services
    • Toxicological & Safety Assessment
  • Modality
    • Large Molecules
    • Small Molecules
  • Indication
    • Cardiovascular Diseases
      • Coronary Artery Disease
      • Heart Failure
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Neurological Disorders
      • Neurodegenerative Disorders
      • Psychiatric Disorders
    • Oncology
      • Hematological Malignancies
      • Solid Tumors
    • Respiratory Disorders
      • Asthma
      • Chronic Obstructive Pulmonary Disease
  • End User
    • Academic & Research Institutions
    • Government & Regulatory Organizations
    • Medical Device Companies
    • Pharmaceuticals & Biotechnology Companies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Altogen Labs
  • Biocytogen Boston Corp.
  • Cellvax, SAS
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • Explicyte by Immusmol SAS Company
  • GEMPHARMATECH LLC
  • ICON Plc
  • Imavita S.A.S.
  • IQVIA Holdings Inc.
  • IVRS AB
  • JSR Corporation
  • Labcorp Drug Development PRIVATE LIMITED
  • Medpace, Inc.
  • Melior Discovery Inc.
  • Noble Life Sciences Inc.
  • Parexel International Corporation
  • Pharmacology Discovery Services Ltd.
  • Pharmaron Beijing Co., Ltd.
  • Pharmatest Services Ltd.
  • PPD Inc. by Thermo Fisher Scientific, Inc.
  • PSI CRO AG
  • Syneos Health Inc.
  • Syngene International Limited
  • Taconic Biosciences, Inc.
  • WuXi AppTec, Inc.
  • Yecuris Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. In Vivo CRO Market, by Type
8.1. Introduction
8.2. Non-Rodent
8.3. Rodent
9. In Vivo CRO Market, by Service Type
9.1. Introduction
9.2. Clinical Services
9.3. Consulting & Strategy
9.4. Laboratory Services
9.5. Preclinical Services
9.6. Regulatory Services
9.7. Toxicological & Safety Assessment
10. In Vivo CRO Market, by Modality
10.1. Introduction
10.2. Large Molecules
10.3. Small Molecules
11. In Vivo CRO Market, by Indication
11.1. Introduction
11.2. Cardiovascular Diseases
11.2.1. Coronary Artery Disease
11.2.2. Heart Failure
11.3. Infectious Diseases
11.3.1. Bacterial Infections
11.3.2. Viral Infections
11.4. Neurological Disorders
11.4.1. Neurodegenerative Disorders
11.4.2. Psychiatric Disorders
11.5. Oncology
11.5.1. Hematological Malignancies
11.5.2. Solid Tumors
11.6. Respiratory Disorders
11.6.1. Asthma
11.6.2. Chronic Obstructive Pulmonary Disease
12. In Vivo CRO Market, by End User
12.1. Introduction
12.2. Academic & Research Institutions
12.3. Government & Regulatory Organizations
12.4. Medical Device Companies
12.5. Pharmaceuticals & Biotechnology Companies
13. Americas In Vivo CRO Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa In Vivo CRO Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific In Vivo CRO Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Altogen Labs
16.3.2. Biocytogen Boston Corp.
16.3.3. Cellvax, SAS
16.3.4. Charles River Laboratories International, Inc.
16.3.5. Crown Bioscience, Inc.
16.3.6. Eurofins Scientific SE
16.3.7. Evotec SE
16.3.8. Explicyte by Immusmol SAS Company
16.3.9. GEMPHARMATECH LLC
16.3.10. ICON Plc
16.3.11. Imavita S.A.S.
16.3.12. IQVIA Holdings Inc.
16.3.13. IVRS AB
16.3.14. JSR Corporation
16.3.15. Labcorp Drug Development PRIVATE LIMITED
16.3.16. Medpace, Inc.
16.3.17. Melior Discovery Inc.
16.3.18. Noble Life Sciences Inc.
16.3.19. Parexel International Corporation
16.3.20. Pharmacology Discovery Services Ltd.
16.3.21. Pharmaron Beijing Co., Ltd.
16.3.22. Pharmatest Services Ltd.
16.3.23. PPD Inc. by Thermo Fisher Scientific, Inc.
16.3.24. PSI CRO AG
16.3.25. Syneos Health Inc.
16.3.26. Syngene International Limited
16.3.27. Taconic Biosciences, Inc.
16.3.28. WuXi AppTec, Inc.
16.3.29. Yecuris Corporation
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IN VIVO CRO MARKET MULTI-CURRENCY
FIGURE 2. IN VIVO CRO MARKET MULTI-LANGUAGE
FIGURE 3. IN VIVO CRO MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IN VIVO CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES IN VIVO CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 67. CANADA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 70. CANADA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 72. CANADA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 73. CANADA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 74. CANADA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 75. CANADA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 76. CANADA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 82. MEXICO IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 83. MEXICO IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. MEXICO IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. GERMANY IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 131. GERMANY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. GERMANY IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 133. GERMANY IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 134. GERMANY IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 136. GERMANY IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. FRANCE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. FRANCE IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 141. FRANCE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. FRANCE IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 143. FRANCE IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 144. FRANCE IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 146. FRANCE IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. ITALY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. ITALY IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 161. ITALY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. ITALY IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 163. ITALY IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 164. ITALY IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 165. ITALY IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. ITALY IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. ITALY IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SPAIN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 171. SPAIN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 173. SPAIN IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 174. SPAIN IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 176. SPAIN IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. DENMARK IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. DENMARK IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 211. DENMARK IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. DENMARK IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 213. DENMARK IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 214. DENMARK IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 216. DENMARK IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. QATAR IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. QATAR IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 230. QATAR IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 231. QATAR IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. QATAR IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 233. QATAR IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 234. QATAR IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 235. QATAR IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. QATAR IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 237. QATAR IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. FINLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. FINLAND IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 241. FINLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 242. FINLAND IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 243. FINLAND IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 244. FINLAND IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. FINLAND IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. EGYPT IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 269. EGYPT IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 271. EGYPT IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. EGYPT IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 273. EGYPT IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 274. EGYPT IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 276. EGYPT IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. TURKEY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 279. TURKEY IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 281. TURKEY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. TURKEY IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 283. TURKEY IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 284. TURKEY IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 286. TURKEY IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. NORWAY IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 299. NORWAY IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 301. NORWAY IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. NORWAY IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 303. NORWAY IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 304. NORWAY IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 306. NORWAY IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. POLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 309. POLAND IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 310. POLAND IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 311. POLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 312. POLAND IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 313. POLAND IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 314. POLAND IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 315. POLAND IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 316. POLAND IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 317. POLAND IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 336. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 338. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 339. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 340. CHINA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 341. CHINA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 342. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 343. CHINA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 344. CHINA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 345. CHINA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 346. CHINA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 347. CHINA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 348. CHINA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. INDIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 350. INDIA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 351. INDIA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 352. INDIA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 353. INDIA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 354. INDIA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 355. INDIA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 356. INDIA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 357. INDIA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 358. INDIA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 359. JAPAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 360. JAPAN IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 361. JAPAN IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 362. JAPAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 363. JAPAN IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 364. JAPAN IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 365. JAPAN IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 366. JAPAN IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 367. JAPAN IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 368. JAPAN IN VIVO CRO MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 369. AUSTRALIA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 370. AUSTRALIA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030

Companies Mentioned

The companies profiled in this In Vivo CRO market report include:
  • Altogen Labs
  • Biocytogen Boston Corp.
  • Cellvax, SAS
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • Explicyte by Immusmol SAS Company
  • GEMPHARMATECH LLC
  • ICON Plc
  • Imavita S.A.S.
  • IQVIA Holdings Inc.
  • IVRS AB
  • JSR Corporation
  • Labcorp Drug Development PRIVATE LIMITED
  • Medpace, Inc.
  • Melior Discovery Inc.
  • Noble Life Sciences Inc.
  • Parexel International Corporation
  • Pharmacology Discovery Services Ltd.
  • Pharmaron Beijing Co., Ltd.
  • Pharmatest Services Ltd.
  • PPD Inc. by Thermo Fisher Scientific, Inc.
  • PSI CRO AG
  • Syneos Health Inc.
  • Syngene International Limited
  • Taconic Biosciences, Inc.
  • WuXi AppTec, Inc.
  • Yecuris Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.5 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type, By Modality, By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type, By Modality, By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
In-vivo CRO Market Report by Type, GLP Type, Indication, and Region 2025-2033 - Product Image

In-vivo CRO Market Report by Type, GLP Type, Indication, and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From
In-Vivo CRO - Global Strategic Business Report - Product Image

In-Vivo CRO - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Oncology Based in-Vivo CRO Market by Animal Model, Route of Administration, Therapeutic Modality, End User - Global Forecast to 2030 - Product Image

Oncology Based in-Vivo CRO Market by Animal Model, Route of Administration, Therapeutic Modality, End User - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
In Vivo Contract Research Organization (CRO) - Global Strategic Business Report - Product Image

In Vivo Contract Research Organization (CRO) - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From

About the Market

The In Vivo CRO market is a subset of the biotechnology industry that focuses on providing contract research services to pharmaceutical and biotechnology companies. These services include preclinical and clinical trials, drug development, and regulatory affairs. In Vivo CRO companies provide expertise in areas such as pharmacology, toxicology, and clinical research. They also provide services such as data management, biostatistics, and medical writing. In Vivo CRO companies are typically small to medium-sized businesses that specialize in a particular area of research. They are often located in countries with a strong biotechnology industry, such as the United States, Canada, and Europe. Some companies in the In Vivo CRO market include Charles River Laboratories, Covance, Parexel, and Quintiles. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.